Aimmune Therapeutics, Inc. (AIMT) Upgraded at Zacks Investment Research
Zacks Investment Research upgraded shares of Aimmune Therapeutics, Inc. (NASDAQ:AIMT) from a sell rating to a hold rating in a research note published on Monday morning.
According to Zacks, “Aimmune Therapeutics, Inc. is a biopharmaceutical company which is engaged in the development of desensitization treatments for peanut and other food allergies. The Company’s characterized oral desensitization immunotherapy includes AR101, a product for the treatment of peanut allergy in children and adults which is in clinical trial stage. Aimmune Therapeutics, Inc. is headquartered in Brisbane, California. “
A number of other analysts also recently weighed in on AIMT. Wedbush restated an ourperform rating and issued a $42.00 target price on shares of Aimmune Therapeutics in a report on Monday, August 14th. BidaskClub downgraded shares of Aimmune Therapeutics from a hold rating to a sell rating in a report on Friday, August 11th. Finally, Piper Jaffray Companies set a $38.00 target price on shares of Aimmune Therapeutics and gave the stock a buy rating in a report on Thursday, July 27th. One research analyst has rated the stock with a sell rating, two have issued a hold rating and one has issued a buy rating to the company’s stock. Aimmune Therapeutics presently has an average rating of Hold and a consensus price target of $40.00.
Shares of Aimmune Therapeutics (AIMT) traded up 0.70% on Monday, hitting $25.90. The stock had a trading volume of 100,032 shares. The stock’s market cap is $1.31 billion. The company has a 50 day moving average price of $24.71 and a 200-day moving average price of $24.71. Aimmune Therapeutics has a 12 month low of $14.87 and a 12 month high of $27.31.
Aimmune Therapeutics (NASDAQ:AIMT) last posted its earnings results on Tuesday, August 8th. The biotechnology company reported ($0.65) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.64) by ($0.01). On average, equities research analysts anticipate that Aimmune Therapeutics will post ($2.71) earnings per share for the current year.
COPYRIGHT VIOLATION NOTICE: “Aimmune Therapeutics, Inc. (AIMT) Upgraded at Zacks Investment Research” was first posted by Watch List News and is the sole property of of Watch List News. If you are reading this report on another website, it was illegally stolen and reposted in violation of US & international copyright and trademark laws. The legal version of this report can be viewed at https://www.watchlistnews.com/aimmune-therapeutics-inc-aimt-upgraded-at-zacks-investment-research/1643725.html.
In related news, insider Susan E. Barrowcliffe sold 6,110 shares of the company’s stock in a transaction dated Tuesday, July 25th. The shares were sold at an average price of $22.00, for a total transaction of $134,420.00. Following the transaction, the insider now directly owns 960 shares in the company, valued at approximately $21,120. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, insider Stephen George Dilly sold 50,000 shares of the company’s stock in a transaction dated Wednesday, July 26th. The shares were sold at an average price of $21.46, for a total transaction of $1,073,000.00. The disclosure for this sale can be found here. Insiders have sold a total of 325,000 shares of company stock worth $7,922,482 over the last quarter. 24.56% of the stock is currently owned by insiders.
A number of large investors have recently modified their holdings of AIMT. SG Americas Securities LLC grew its holdings in Aimmune Therapeutics by 10.1% during the 2nd quarter. SG Americas Securities LLC now owns 5,451 shares of the biotechnology company’s stock valued at $112,000 after purchasing an additional 499 shares during the last quarter. Legal & General Group Plc grew its holdings in Aimmune Therapeutics by 26.6% during the 2nd quarter. Legal & General Group Plc now owns 7,776 shares of the biotechnology company’s stock valued at $160,000 after purchasing an additional 1,634 shares during the last quarter. Voya Investment Management LLC grew its holdings in Aimmune Therapeutics by 31.2% during the 2nd quarter. Voya Investment Management LLC now owns 15,781 shares of the biotechnology company’s stock valued at $324,000 after purchasing an additional 3,757 shares during the last quarter. DekaBank Deutsche Girozentrale bought a new position in Aimmune Therapeutics during the 2nd quarter valued at about $333,000. Finally, American International Group Inc. grew its holdings in Aimmune Therapeutics by 7.1% during the 1st quarter. American International Group Inc. now owns 16,184 shares of the biotechnology company’s stock valued at $352,000 after purchasing an additional 1,070 shares during the last quarter. Institutional investors own 72.90% of the company’s stock.
About Aimmune Therapeutics
Aimmune Therapeutics, Inc is a clinical-stage biopharmaceutical company developing a therapeutic approach, including the development of product candidates, for the treatment of peanut and other food allergies. The Company’s therapeutic approach, which it refers to as Characterized Oral Desensitization Immunotherapy (CODIT), is a system designed to desensitize patients to food allergens using characterized biologic products, defined treatment protocols and support services.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Aimmune Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aimmune Therapeutics Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.